Lecture 12: HW review

Question 1

ECOG status

Answer 1

-0-4
1: restrivted in activity
2: no work activitys, awake >50%
3: limited self-care, confined to bed >50%
4: completely disabled

Question 2

PD1/PDL1

Answer 2

-biomarkers to determine if pt will benefit from immunotherapy
-Pembrolizumab may be effective in tumors w mismatch repair deficiency (dMMR)
-PD1 vs PDL1 = PD1 on T cell, PDL1 on cancer
-prefer PDL1 expression bc that is expressed by cancer cell

Question 3

PD1 blockers

Answer 3

-Pembrolizumab
-Nivolumab
-Cemiplimab

Question 4

PDL-1 blockers

Answer 4

-Atezolizumab
-Avelumab
-Durvalumab

Question 5

BRAC1 mutations

Answer 5

-by blocking PARP, both both PARP and BRAC mediated pathways can’t repair DNA
=synthetic lethality if PARP and BRAC are both mutated

Question 6

Synthetic lethality

Answer 6

-PARP and BRAC normally each repair DNA
-if both are blocked = no DNA
-BRAC mutation = loss of function

Question 7

PARP inhibitors (BRAC inhibtion)

Answer 7

-Niraparib
-Olaparib
-Rucaparib
-Talazoparib

Question 8

KRAS G12V inhibition

Answer 8

-may activate RAF-MEK and PI3K
-Idelalisib
-Copanlisib
-Duvelisib

-cant use AMG510 in KRASG12c mutation?

Question 9

MEK inhibitors

Answer 9

-binimetinib
-cobimetinib
-trametinib

Question 10

CDKN2A/B

Answer 10

-encodes tumor suppressors

Question 11

CDKN2A/B loss

Answer 11

-cancer cells may be sensitive to CDK4/6 inhibition

Question 12

CDK 4 and CDK 6 inhibitors

Answer 12

-Palbociclib
-Ribociclib
-Abemaciclib